Table 2 Viral testing and overall serology results among students included in serology cohort investigation from two universities in Wisconsin (August 21–November 14, 2020)
From: A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students
Serology testing characteristics | |||
|---|---|---|---|
SARS-CoV-2 IgG assay (anti-nucleocapsid) | University A (N = 70) | University B (N = 37) | Total (N = 107) |
Number of students who tested positive at semester start (%) | 7 (10.0%) | 8 (21.6%) | 15 (14.0%) |
Number of students who tested positive at semester end (%) | 19 (27.1%) | 10 (27.0%) | 29 (27.1%) |
p-valuea | 0.11 | 0.74 | 0.22 |
AdviseDx SARS-CoV-2 IgG II assay (anti-spike) | University A (N = 69) | University B (N = 36) | Total (N = 105)b |
|---|---|---|---|
Number of students who tested positive at semester start (%) | 10 (14.5%) | 7 (19.4%) | 17 (16.2%) |
Number of Students who tested positive at semester end (%) | 29 (42.0%) | 13 (36.1%) | 42 (40.0%) |
p-valuea | 0.89 | 0.64 | 0.073 |
Viral testing characteristics | University Ac (N = 70) | University Bd (N = 36)e | Total (N = 106) |
|---|---|---|---|
Median number of viral tests over the semester per student (range) | 9 (1–13) | 10 (2–15) | 9 (1–15) |
Number of students with positive viral test before semester (%)f | 2 (2.9%) | 2 (5.6%) | 4 (3.8%) |
Number of students who tested positive during serial viral testing (%) | 20 (28.6%) | 3 (8.3%) | 23 (21.7%) |